Ascletis Pharma Inc.
1672
Rangering i aksjer
#10749
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Aksjekurs
$0.70092358
Markedsverdi
$735.73M
Endring (1 dag)
-7.64%
Endring (1 år)
-39.58%
Land
CN
Handel Ascletis Pharma Inc. (1672)
Kategori
Healthcare
Aksjeprishistorikk for Ascletis Pharma Inc. (1672)
Høyeste sluttskurs: $0.92 den 2026-10-01
Laveste sluttskurs: $0.60 den 2019-11-01
Laveste sluttskurs: $0.60 den 2019-11-01
Aksjeprishistorikk for Ascletis Pharma Inc. fra 2019 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -10.71% |
| 2025 | 759.36% |
| 2024 | 9.90% |
| 2023 | -65.45% |
| 2022 | 11,939.80% |
| 2021 | -98.81% |
| 2020 | -40.55% |
| 2019 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
